Jon Faiz Kayyem

Director

Jon Faiz Kayyem (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Inhibrx Biosciences, Inc. (INBX). The largest single filing was $568K of INBX (5,000 sh × $113.52, as filed), executed Sep 8. The median gap between execution and disclosure was 0 days.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

purchases not yet priced

Delay-adjustediThe same average, entered at disclosure dates

–

purchases not yet priced

Filings, ttm

2 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$1.1M

shares × price, as filed

Last traded

Sep 16

Filed Sep 17

Median ADV $33.6M across their filed names

100% of their measured filings could not be priced (delisted or unquoted names). The returns above cover only what still trades.

Open performance→

Volume by month

Buys $2.6M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 2 filings

Sector per market data · by filing · past 12 months

Most traded names

INBX Inhibrx Biosciences, Inc. INBX · 3 buys · 0 sells 3 filings

Recent filings

INBXPURCHASE Inhibrx Biosciences, Inc. View filing → $500K
5,000 sh × $100.00
Exec Sep 16
Filed Sep 17 · 5:46 PM ET INBXPURCHASE Inhibrx Biosciences, Inc. View filing → $568K
5,000 sh × $113.52
Exec Sep 8
Filed Sep 8 · 5:23 PM ET INBXPURCHASE Inhibrx Biosciences, Inc. View filing → $1.5M
107,186 sh across 4 lots
Exec Nov 19 2024
Filed Nov 22 2024 · 5:30 PM ET †